Objective: To investigate the influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction. Methods: A total of 1...Objective: To investigate the influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction. Methods: A total of 177 cases of patients with convalescent cerebral infarction were retrospectively reviewed and then divided into the control group (n=109) and the Xiaoshuan enteric-coated capsules group (n=68). Control group received aniracetam therapy on the basis of routine treatment, and Xiaoshuan enteric-coated capsules group received Xiaoshuan enteric-coated capsules + aniracetam therapy on the basis of routine treatment. The differences in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents were compared between the two groups. Results: Before treatment, there was no statistically significant difference in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents between the two groups. After treatment, ultrasound cerebral blood perfusion parameters PSV and TMV levels in Xiaoshuan enteric-coated capsules group were higher than those in control group whereas RI level was lower than that in control group;serum neurotrophy indexes bFGF, BDNF and VEGF contents were higher than those of control group;serum nerve injury indexes GFAP, NSE, UCH-L1 and S100B contents were lower than those of control group. Conclusion: Xiaoshuan enteric-coated capsules + aniracetam therapy can significantly increase cerebral blood perfusion and optimize nerve function in patients with convalescent cerebral infarction.展开更多
Objective： To investigate the molecular mechanisms by which Qianliening Capsule （前列宁胶囊,QC） treats benign prostatic hyperplasia （BPH）. Methods： Human prostate stromal cell line WPMY1 was treated with 0, 1, 3...Objective： To investigate the molecular mechanisms by which Qianliening Capsule （前列宁胶囊,QC） treats benign prostatic hyperplasia （BPH）. Methods： Human prostate stromal cell line WPMY1 was treated with 0, 1, 3 and 5 mg/mL of QC for 24, 48 and 72 h, respectively, in the presence of 10 ng/mL basic fibroblast growth factor （bFGF）. The viability of WPMY1 cells was determined by 3（4,5Dimethylthiazol2yl）2,5diphenyltetrazolium bromide （M＇lr） assay. Cell morphology was observed by phasecontrast microscopy. 4＇,6diamidino2phenylindole （DAPI） staining and fluorescence activated cell sorting （FACS） analysis with AnnexinV/propidium iodide （PI） staining were performed to determine cell apoptosis. The loss of mitochondrial membrane potential was examined by FACS analysis with 5,5＇,6,6＇tetrachloro1 ,l＇,3,3＇tetraethylbenzimidazolylcarbocyadne iodide （JC1） staining. Activation of caspase3 and 9 was evaluated by colorimetric assay. The mRNA and protein expression levels of Bcl2 and Bax were measured by reverse transcription polymerase chain reaction （RTPCR） and Western blotting, respectively. Results： Upon bFGF stimulation, the viability of WPMY1 cells was increased to 122%118% compared with the control cells （P〈0.05）. However, treatment with 15 mg/mL of QC for 24, 48 and 72 h decreased the viability of bFGFsUmulated cells to 80%92%, 59%82%, 36%62% compared with the untreated cells （P〈0.05）. In addition, QC treatment reduced WPMY1 cell density in a dosedependent manner. Moreover, QC treatment dosedependently induced the loss of plasma membrane asymmetry, the nuclear condensation and fragmentation, collapse of mitochondrial membrane potential, activation of caspase9 and caspase3, and increase of proapoptotic Bax/Bcl2 ratio. Conclusion： Promoting mitochondriondependent apoptosis of prostate stromal cells might be one of the mechanisms by which QC treats BPH.展开更多
Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-co...Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-coated aspirin aged 40-75 years were enrolled in Beijing Anzhen Hospital,Capital Medical University from January 2019 to December 2019.The patients continued taking aspirin Tablet(100 mg per day)and underwent MCCE before and after 1-month combined treatment with WKC(0.9 g per time orally,3 times per day).The gastrointestinal symptom score,gastric Lanza score,the duodenal,jejunal and ileal mucosal injury scores were used to evaluate the gastrointestinal injury before and after treatment.Adverse events including nausea,vomiting,abdominal pain,abdominal distension,abdominal discomfort,dizziness,or headache during MCCE and combined treatment were observed and recorded.Results Twenty-two patients(male/female,13/9)taking enteric-coated aspirin aged 59.5±11.3 years with a duration of aspirin use of 28.0(1.0,48.0)months were recruited.Compared with pre-treatment,the gastrointestinal symptom rating scale scores,gastric Lanza scores,and duodenal mucosal injury scores were significantly reduced after 1-month WKC treatment(P<0.05),and jejunal and ileal mucosal injury scores showed no obvious change.No adverse events occurred during the trial.Conclusions WKC can alleviate gastrointestinal symptoms,as well as gastric and duodenal mucosal injuries,in patients taking enteric-coated aspirin;it does not aggravate jejunal or ileal mucosal injury,which may be an effective alternative for these patients(Clinical trial registry No.ChiCTR1900025451).展开更多
Background Elevated fibrinogen （Fg） level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess...Background Elevated fibrinogen （Fg） level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess the effects of one-year therapy with oral lumbrokinase enteric-coated capsules on secondary ischemic stroke prevention.展开更多
文摘Objective: To investigate the influence of Xiaoshuan enteric-coated capsules + aniracetam therapy on cerebral blood perfusion and nerve function in patients with convalescent cerebral infarction. Methods: A total of 177 cases of patients with convalescent cerebral infarction were retrospectively reviewed and then divided into the control group (n=109) and the Xiaoshuan enteric-coated capsules group (n=68). Control group received aniracetam therapy on the basis of routine treatment, and Xiaoshuan enteric-coated capsules group received Xiaoshuan enteric-coated capsules + aniracetam therapy on the basis of routine treatment. The differences in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents were compared between the two groups. Results: Before treatment, there was no statistically significant difference in ultrasound cerebral blood perfusion parameter levels as well as serum neurotrophy index and nerve injury index contents between the two groups. After treatment, ultrasound cerebral blood perfusion parameters PSV and TMV levels in Xiaoshuan enteric-coated capsules group were higher than those in control group whereas RI level was lower than that in control group;serum neurotrophy indexes bFGF, BDNF and VEGF contents were higher than those of control group;serum nerve injury indexes GFAP, NSE, UCH-L1 and S100B contents were lower than those of control group. Conclusion: Xiaoshuan enteric-coated capsules + aniracetam therapy can significantly increase cerebral blood perfusion and optimize nerve function in patients with convalescent cerebral infarction.
基金Supported by the National Natural Science Foundation of China(No.81072927 and No.81173433)the Natural Science Foundation of Fujian Province of China(No.2010J01199 and No.2009J01169)
文摘Objective： To investigate the molecular mechanisms by which Qianliening Capsule （前列宁胶囊,QC） treats benign prostatic hyperplasia （BPH）. Methods： Human prostate stromal cell line WPMY1 was treated with 0, 1, 3 and 5 mg/mL of QC for 24, 48 and 72 h, respectively, in the presence of 10 ng/mL basic fibroblast growth factor （bFGF）. The viability of WPMY1 cells was determined by 3（4,5Dimethylthiazol2yl）2,5diphenyltetrazolium bromide （M＇lr） assay. Cell morphology was observed by phasecontrast microscopy. 4＇,6diamidino2phenylindole （DAPI） staining and fluorescence activated cell sorting （FACS） analysis with AnnexinV/propidium iodide （PI） staining were performed to determine cell apoptosis. The loss of mitochondrial membrane potential was examined by FACS analysis with 5,5＇,6,6＇tetrachloro1 ,l＇,3,3＇tetraethylbenzimidazolylcarbocyadne iodide （JC1） staining. Activation of caspase3 and 9 was evaluated by colorimetric assay. The mRNA and protein expression levels of Bcl2 and Bax were measured by reverse transcription polymerase chain reaction （RTPCR） and Western blotting, respectively. Results： Upon bFGF stimulation, the viability of WPMY1 cells was increased to 122%118% compared with the control cells （P〈0.05）. However, treatment with 15 mg/mL of QC for 24, 48 and 72 h decreased the viability of bFGFsUmulated cells to 80%92%, 59%82%, 36%62% compared with the untreated cells （P〈0.05）. In addition, QC treatment reduced WPMY1 cell density in a dosedependent manner. Moreover, QC treatment dosedependently induced the loss of plasma membrane asymmetry, the nuclear condensation and fragmentation, collapse of mitochondrial membrane potential, activation of caspase9 and caspase3, and increase of proapoptotic Bax/Bcl2 ratio. Conclusion： Promoting mitochondriondependent apoptosis of prostate stromal cells might be one of the mechanisms by which QC treats BPH.
基金Supported by Beijing Chinese Medicine Science and Technology Development Fund(No.JJ2018-02)。
文摘Objective To investigate the effects of Weikang Capsule(胃康胶囊,WKC)on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy(MCCE).Methods Patients taking enteric-coated aspirin aged 40-75 years were enrolled in Beijing Anzhen Hospital,Capital Medical University from January 2019 to December 2019.The patients continued taking aspirin Tablet(100 mg per day)and underwent MCCE before and after 1-month combined treatment with WKC(0.9 g per time orally,3 times per day).The gastrointestinal symptom score,gastric Lanza score,the duodenal,jejunal and ileal mucosal injury scores were used to evaluate the gastrointestinal injury before and after treatment.Adverse events including nausea,vomiting,abdominal pain,abdominal distension,abdominal discomfort,dizziness,or headache during MCCE and combined treatment were observed and recorded.Results Twenty-two patients(male/female,13/9)taking enteric-coated aspirin aged 59.5±11.3 years with a duration of aspirin use of 28.0(1.0,48.0)months were recruited.Compared with pre-treatment,the gastrointestinal symptom rating scale scores,gastric Lanza scores,and duodenal mucosal injury scores were significantly reduced after 1-month WKC treatment(P<0.05),and jejunal and ileal mucosal injury scores showed no obvious change.No adverse events occurred during the trial.Conclusions WKC can alleviate gastrointestinal symptoms,as well as gastric and duodenal mucosal injuries,in patients taking enteric-coated aspirin;it does not aggravate jejunal or ileal mucosal injury,which may be an effective alternative for these patients(Clinical trial registry No.ChiCTR1900025451).
文摘Background Elevated fibrinogen （Fg） level is a known risk factor for ischemic stroke. There are few clinical trials on oral fibrinogen-depleting therapies for secondary ischemic stroke prevention. We aimed to assess the effects of one-year therapy with oral lumbrokinase enteric-coated capsules on secondary ischemic stroke prevention.
